semaglutide dvt risk and Blood Clots: What the Evidence Shows Ozempic and Blood Clots: Evidence,

This treatment is often particularly beneficial for adults who: Have a body mass index (BMI) of 30 or higher Have a BMI of 27 or higher and also have at least one weight-related health condition, like high blood pressure, type 2 diabetes, or high cholesterol

In the CY 2025 OPPS/ASC final rule with comment period (89 FR 93964 through 93965), we applied this policy and calculated the relative payment weights for each APC for CY 2025 that were shown in Addenda A and B of the CY 2025 OPPS/ASC final rule with comment period (which were made available via the internet on the CMS website) using the APC costs discussed in sections II.A.1

The approval of semaglutide, a GLP-1 agonist for the treatment of MASH, followed this development

Inoue et al., 2016